Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision...

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Antibody-drug conjugates targeting folate receptor alpha (FRα) offer potential for platinum-resistant ovarian cancer (OC).
• Accurate assessment of FRα expression remains a challenge for effective treatment selection.
• Understanding FRα gene expression and associated mRNA signatures in OC is crucial.

Purpose of the Study:

• To investigate FRα gene expression patterns in ovarian cancer.
• To identify mRNA signatures correlated with FRα expression and clinical outcomes in OC.
• To evaluate the potential of FRα-related signatures for refining therapeutic strategies in OC.

Main Methods:

• Pooled gene expression data from 16 public datasets (1832 OC, 30 normal tissues).
• Integrated DNA copy number, methylation (TCGA), and protein expression data (Cancer Cell Line Encyclopedia).
• Analyzed correlations between FOLR1 mRNA, protein expression, clinicopathological features, and survival.

Main Results:

• FOLR1 mRNA expression significantly higher in OC than normal tissues (OR = 3.88, p = 6.97 × 10^-12) and correlated with protein levels.
• High FOLR1 expression associated with serous histology, advanced stage, and high grade, but not platinum sensitivity or prognosis.
• A 187-gene signature linked to high FOLR1 expression significantly improved survival (HR = 0.71, p = 1.18 × 10^-6), independent of clinical factors.

Conclusions:

• A novel 187-gene expression signature correlates with high FRα expression and improved prognosis in ovarian cancer.
• This signature may help refine therapeutic strategies targeting FRα in OC.
• Further validation in larger cohorts is warranted to confirm these findings.